ArticleFrontiers in immunology2026
Clinical superiority of HBV RNA testing in patients with chronic hepatitis B.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to thoroughly investigate the detection levels of serum Hepatitis B Virus RNA (HBV RNA) and its clinical significance in Chronic Hepatitis B (CHB) patients before and after treatment. Methods: Serum samples were collected from 487 chronic hepatitis B patients. First, the positivity rate and levels of serum HBV RNA were compared with other relevant indicators, and correlations were examined between untreated and treated CHB patients. Second, treated CHB patients were grouped based on their HBsAg, HBeAg, and HBV DNA status. Differences and correlations between HBV RNA and relevant indicators were further analyzed among the groups. Results: Among the 487 patients, the positivity rate of HBV RNA was significantly higher than that of both HBV DNA and HBeAg. In the untreated group, the positivity rates of both HBV RNA and HBV DNA were significantly higher than that of HBeAg. In patients who were treated but not cured, the positivity rate of HBV RNA was significantly higher than that of both HBV DNA and HBeAg, regardless of whether patients were grouped based on HBsAg, HBeAg, or HBV DNA levels. When analyzed at specific monitoring levels, patients in the treated group showed significantly lower levels of serum HBV RNA, HBV DNA, HBeAg, HBsAg, ALT, and AST compared to those in the untreated group. Correlation analysis revealed that in untreated patients, HBV RNA was positively correlated with ALT, AST, HBsAg, HBeAg, and HBV DNA. However, in the treated group and in those with low HBsAg, HBeAg, and HBV DNA levels, the correlation between HBV RNA and other markers was weakened. Conclusion: HBV RNA exhibits greater sensitivity and accuracy in reflecting the status of viruses, particularly in patients undergoing antiviral therapy. It provides unique advantages in monitoring treatment efficacy and assessing persistent viral transcriptional activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.